Silo Pharma Inc. has announced promising data from a preclinical study investigating the binding affinity and optimization of SPU-21 liposomal joint homing peptide in human synovial tissue surrounding joints and tendons.
Peptidream Inc. has entered into a new multitarget collaboration and license agreement with Genentech, a member of the Roche Group, focused on the discovery and development of novel macrocyclic peptide-radioisotope drug conjugates.
Evergreen Discovery (Evergreen Theragnostics Inc.) and Orbit Discovery Ltd. have entered into a collaboration to identify specific cell-targeting peptides and advance the development of novel radiopharmaceuticals.
Silo Pharma Inc. plans to initiate a pilot study of SPU-21, its novel joint-homing peptide targeting rheumatoid arthritis (RA), in human synovial tissue surrounding joints and tendons.
Vivasc Therapeutics Inc. has initiated work under a second National Institutes of Health (NIH) phase I STTR research grant, in conjunction with Georgetown University.
Antimicrobial peptides (AMPs) are a type of active peptide produced by the organism that are important host-defense factors, with broad-spectrum antibacterial properties, as well as significant properties such as antifungal and antiviral activity and immune regulation, among others.
RSS
